Read review Dihexa for Migraine & Chronic Migraine The May 2024 NICE TA973 atogepant (Aquipta, AbbVie) approval, the rimegepant / erenumab / galcanezumab / fremanezumab / eptinezumab CGRP pathway, 2025 chronic-migraine hippocampal atrophy & accelerated brain ageing research, the Tanure BDNF-elevated-in-attack paradox, NICE NG150, and the ~10 million UK migraine population
Deep sleep facilitates physical repair, and combining these peptides may enhance athletic recovery protocols
Gallbladder events Rapid weight loss is associated with gallstone formation independent of the agent producing the loss
Expecting noticeable scalp health improvements by 8 weeks, visible new growth by 4 months, and meaningful density changes by 6-8 months creates a structured framework for evaluation
Read clinical review Comparisons BPC-157 Compounding Pharmacy: Research-Only vs Medical-Grade Peptides Explained A physician-reviewed guide to BPC-157 sourcing: how research-grade and compounded medical-grade peptides differ by regulation, purity testing, and legal status in 2024